Growth funding Tucuvi has secured a total of $24M in funding, including a Series A of $20M in early January 2026 and a seed round of $3M prior to that. This indicates strong investor confidence and potential for scaled go-to-market efforts, making it a favorable time to explore enterprise partnerships and multi-year contracts with healthcare systems.

Enterprise validation The platform is already deployed across 60+ healthcare organizations, delivering high automation (up to 80% of nursing workflows) and >90% patient engagement. This track record demonstrates credible ROI potential for hospital networks seeking scalable AI-enabled care coordination and proactive management.

Regulatory edge Tucuvi is the first Class IIb SaMD approved AI platform in Europe for its Voice AI agent and patient management, underscoring regulatory credibility and trust. This positions the company well for large European health systems prioritizing compliant, clinically validated AI solutions.

Broad clinical scope With support for 50+ care workflows spanning care transitions, chronic disease management, screenings, scheduling, and medication management, Tucuvi offers a broad value proposition for hospitals looking to modernize multiple care pathways within a single platform.

Market momentum Recent growth signals include rapid funding rounds in 2026 and recognition from industry awards, suggesting accelerating market adoption and a favorable competitive environment for AI-driven care management players targeting hospitals and health systems.